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Abstract A double-blinded, placebo-controlled cross-over trial 
was carried out with 27 hypercholesterolemic men with coronary 
heart disease. During the 6-week treatment period lovastatin (60 
mg/day) decreased fasting serum LDL cholesterol by 45%, LDL 
phosphorus by 38% and apoB by 33%. Ubiquinol content 
diminished by 13% as measured per LDL phosphorus. When 
LDL was oxidized ex vivo with AMVN both LDL ubiquinol and 
a-tocopherol were exhausted faster after lovastatin treatment 
compared to placebo, by 24% (P < 0.005) and 36% (P < 0.0001), 
respectively. Lag time in copper-induced oxidation of LDL 
decreased by 7% (P < 0.01). This suggests diminished antiox-
idant-dependent resistance of LDL to the early phase of 
oxidative stress. 
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1. Introduction 
The 3-hydroxy-3-methylglutaryl-coenzyme A reductase 
( H M G - C o A reductase) inhibitors or statins are widely used 
drugs in hypercholesterolemia. They affect the early key en-
zyme of the mevalonate pathway. Doing so, the statins do not 
only inhibit the synthesis of cholesterol but also other non-
sterol end products, such as coenzyme Qi 0 or ubiquinone 
(CoQ) [1]. In most human tissues it appears mainly in its 
reduced form, ubiqumol (CoQOH or ubiquinol-10) which 
acts as a powerful antioxidant even in low concentrations [2]. 
The plasma L D L cholesterol to ubiquinone ratio has been a 
more remarkable risk factor of coronary heart disease (CHD) 
than the more familiar total cholesterol to H D L cholesterol 
ratio [3]. After the initiation of a peroxidative insult against 
L D L the production of lipid hydroperoxides does not begin 
until most of ubiquinol has been oxidized [4]. It protects a-
tocopherol from oxidation, possibly through efficient reduc-
tion of the tocopheroxyl radical [5,6]. Some lipid peroxidation 
occurs already during the measured lag phase when conju-
gated diene formation is not yet fully propagated. In a meth-
od using parinaric acid as a probe, its oxidation occurs im-
mediately upon consumption of ubiqumol and a-tocopherol 
[7]. Hence, the depletion of these lipid-soluble antioxidants 
makes the initiation of oxidative modification of L D L possi-
ble [4,6,7]. 
There are no publications on the rate of antioxidant con-
sumption during radical attack to L D L during statin treat-
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1 Deceased during the study. 
ment. We studied if lovastatin treatment diminishes LDL 
ubiquinol or a-tocopherol contents, or affects the consump-
tion of those antioxidants in oxidative stress indicating a 
change in the L D L antioxidative capacity. 
2. Materials and methods 
2.1. Study design 
A randomized, double-blinded cross-over study, where the effects of 
lovastatin treatment were compared to those of placebo, was carried 
out in the cardiology outpatient clinic at Kanta-Hame Central Hos-
pital, Hameenlinna, Finland. The study was carried out according to 
the recommendations of the Declaration of Helsinki and monitored 
according to the Good Clinical Trial Practice [8]. It was approved by 
the Ethical Committee of Kanta-Hame Central Hospital and the Na-
tional Agency for Medicines. Every patient gave a written informed 
consent before entering the study. 
On the pre-study visit the inclusion criteria were checked and a 
wash-out of at least 6 weeks begun where any treatment affecting lipid 
metabolism was prohibited. The HMG CoA reductase inhibitor used 
was Lovacol (20 mg lovastatin; Orion, Finland under license from 
MSD). The patients took daily one lovastatin 20 mg or an identical 
placebo tablet during the 1st week, two tablets/day on the 2nd week 
and three tablets daily on weeks 3-6. No concomitant lipid lowering 
agents or vitamins were allowed. All other medications were kept 
constant during the whole study. Compliance was checked by tablet 
counting. Assessment of the diet was made on each visit. Safety of the 
therapy was evaluated by frequent clinical visits, ECG and analyzing 
serum enzymes indicating the function of the muscles, liver and kid-
neys. 
2.2. Subjects 
The patients with verified CHD and primary hyperlipidemia were 
included in the study. The definitions of CHD were either an angio-
graphically determined occlusion/obliteration in coronary vessels (19 
patients) or a previous heart infarction (9 patients). The patients had 
not had a myocardial infarction within 6 months before the study. 
The inclusion criteria for fasting serum lipids were as follows: LDL-
cholesterol > 4.0 mmol/1 or total/HDL-cholesterol ratio > 5.5. All the 
patients were on cholesterol-lowering diet. Exclusion criteria were 
concomitant steroid therapy, diabetes, alcoholism or misuse of nar-
cotics, overt hypertriglyceridemia ( > 5 mmol/1), liver, renal or endo-
crine disease, malignant tumor or chronic terminal disease. 
28 men with the age of 56 ± 8 years (mean ± S.D., range 41-69) were 
selected in the study. They were well-informed and co-operative. 12 
patients had undergone previous coronary artery bypass grafting and 
3 had had coronary angioplasty. 16 patients had apolipoprotein E 
(apoE) phenotype E3/3, 10 had E3/4 and 2 had E4/4. Three of the 
men were current smokers. 25 of the patients were on p-blocking 
agent therapy and 26 on acetosalisylic acid. Two patients used also 
an ACE-inhibitor, 9 a long-acting nitrate and 8 had a calcium channel 
blocking agent. Additional patient characteristics are compiled in Ta-
ble 1. 
2.3. Blood samples 
Venous blood samples were drawn between 08:00 and 09:00 h on 
the study visits, before and after the 6-week treatment periods. The 
patients were advised not to eat, take any medication, drink coffee or 
other beverages, or smoke 12 h before the venipuncture. Alcohol was 
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prohibited for 36 h before sampling. Blood samples were drawn in 
sitting position after a rest of at least 15 min. Plasma was separated by 
centrifugation immediately after cooling (5 min) the sample in ice in 
the dark. After separation, the samples were frozen and stored at 
-80°C until analyzed. 
2.4. Oxidation of LDL with AMVN 
LDL was precipitated from 2 ml EDTA-plasma with 75 ul heparin 
(5000 IU/ml, Noparin, Novo Nordisk) and 7.5 ml trisodiumcitrate (64 
mmol/1 pH 5.0) in acid-washed Kimax glass tubes [9]. The supernatant 
was very carefully removed after centrifugation under nitrogen atmos-
phere and the precipitated LDL fraction was dissolved in 2 ml of 
chloroform: methanol (1 :1). After shaking, 2*100 ul samples were 
taken for the measurement of phosphorus, lipid-soluble a-tocopherol 
and ubiquinol, and 1 ml was used in the LDL oxidation experiment. 
Peroxyl radicals were produced at a constant rate by the thermal 
decomposition of 2,2-azobis(2,4-dimethylvaleronitrile) (AMVN, Poly-
sciences, Warrington, PA) [10] dissolved in benzene. The test tube was 
placed in a temperature-controlled incubator (37°C), and the reaction 
was initiated by mixing 94 ul AMVN solution (final concentration 2.1 
mmol/1) with 1 ml chloroform : methanol (1 :1) containing LDL. 100 
ul samples were taken every 3 min during half an hour for the deter-
mination of a-tocopherol and ubiquinol. Oxidation was stopped by 
deep-freezing the samples in liquid nitrogen where they were stored 
until HPLC-analyses. 
2.5. Determination of reduced ubiquinol and a-tocopherol 
Ubiquinol and a-tocopherol were determined with an HPLC meth-
od modified from a previously published procedure [11]. The equip-
ment consisted of a pump (LKB 2150, Bromma, Sweden), a reversed-
phase column (Super Pac Spherisorb ODS 2.5 um, Pharmacia, Upp-
sala, Sweden) and a redox-sensitive electrochemical detector (Antec, 
Leiden, The Netherlands). The mobile phase was methanol: ethanol: 
isopropanol in the ratio 65 :33 :2 containing lithium perchlorate 20 
mmol/1, and its flow rate was 1 ml/min at 22°C. The internal standard 
for ubiquinol was coenzyme Qg with nine isoprenoid units (Sigma, St. 
Louis, MO) and that for a-tocopherol was tocol (Roche, Basel, Swit-
zerland). The retention times of tocol, a-tocopherol, Qg and ubiquinol 
were 3.3, 4.3, 9.3 and 12.6 min, respectively. All plasma samples of 
each individual patient from all periods were analyzed in the same run 
with known calibration samples prepared using d-a-tocopherol (Ko-
dak, Rochester, NY) and ubidecarone (coenzyme Qio, Pharma Nord, 
Denmark). The lowest calibration concentration used was 1.67 umol/1 
and the highest 33.4 umol/1 for a-tocopherol, and 76 nmol/1 and 1530 
nmol/1 for ubiquinol. The detection limit was defined as 1 umol/1 for 
a-tocopherol and 50 nmol/1 for ubiquinol. The mean value of the 
signal/noise-ratio at the specified detection limits was ~ 4 . Because 
the recovery is variable due to manual extraction of LDL, the results 
are standardized with LDL phosphorus (inorganic) and expressed as 
mmol of a-tocopherol or ubiquinol per mol of LDL phosphorus. 
2.6. Oxidation of LDL with CuSO\ 
LDL was isolated with a single-step ultracentrifugation (Beckman 
TL-100, Palo Alto, CA) using TLV-100 rotor. 0.57 ml plasma density 
adjusted to 1.21 g/ml by adding 0.4664 KBr mg per 1 ml plasma was 
added carefully on 1.43 ml of NaCl solution with density of 1.006 g/ 
ml. After ultracentrifugation at 10°C for 30 min at 338 000 G sample 
of LDL was taken with a needle punctured horizontally through the 
vial wall. LDL was first desalted and made free of EDTA by gel 
Table 1 
Demographic and metabolic parameters in fasting serum sample before 
Parameter Before treatments 
and after wash-out 
Body mass index kg/m2 27.1 ±0.5 
Systolic sitting blood pressure mm Hg 147 ±4 
Diastolic sitting blood pressure mm Hg 88 ± 2 
Heart rate beat/min 60 ± 2 
Ethanol consumption g/week 142 ±28 
S-creatinine umol/1 93.9 ± 1.8 
S-urate umol/1 359 ±13 
S-alanine aminotransferase U/l 27.0 ±2.4 
S-creatine kinase U/l 109 ± 10 
filtration with an Econo-Pac 10 DG column (Bio-Rad Laboratories, 
CA) using phosphate buffer (PBS pH 7.4) as eluent. A 50 ul sample 
was taken for protein determination [12]. 1-ml sample of LDL solu-
tion standardized to 0.05 mg protein/ml with PBS was oxidized at 
37°C as described previously [13], The final concentration of Q1SO4 
in the mixture was 1.67 umol/1. UV-absorbance at 234 nm was moni-
tored every 1 min during 300 min using Perkin-Elmer Lambda Bio 10 
(Uberlingen, Germany) spectrometer. Lag time to the start of the 
propagation phase of diene formation was defined as the crossing of 
the tangents of the initial phase (first 5 min) and the maximal prop-
agation. The maximal concentration of conjugated dienes is presented 
as a proportion to protein content in LDL fraction. All the samples of 
an individual patient were analyzed in one run. 
2.7. Determination of lipids, apolipoproteins and apoEphenotype 
Total cholesterol, HDL-cholesterol and triglycerides were analyzed 
immediately after the separation of serum samples. LDL-cholesterol 
was calculated using Friedewald's formula. Apolipoprotein A-I and B 
(apoB) were measured by a nephelometric method using highly spe-
cific antisera (rabbit, OUED 14/15 for apoA-I, OSAN 14/15 for apoB, 
Behring; Behring Laser Nephelometer, Behringswerke, Marburg, Ger-
many). LDL phosphorus (Pi) concentration was determined using an 
inorganic ammonium molybdate reaction with colorimetric detection 
at 799 nm [14]. 4-Hydroxy-m-phenylenediammonium chloride was 
used as the reducing agent [15], The lowest calibration concentration 
was 161 umol/1. ApoE phenotypes were determined from delipidated 
fasting plasma after isoelectric focusing and cysteamine treatment us-
ing an immunoblotting technique [16]. 
2.8. Numerical analyses 
Rates of individual consumption of ubiquinol and a-tocopherol 
were calculated using linear regression analysis. In case of non-normal 
distribution (D'Agostino's test: P<0.05), a logarithmic transforma-
tion was carried out for the comparison with a parametric test. The 
effects of the lovastatin and placebo interventions were compared 
using the two-way analysis of variance with equal replications, and 
with the factors treatment and treatment order. Results of two-sided 
tests with P values of < 0.05 are regarded as statistically significant. 
Mean ± S.E.M values are presented if not otherwise cited. 
3. Results 
The clinical phase of the study was carried out between 
August and December. N o severe adverse effect was reported 
or observed during the whole trial. Patient compliance was 
good as measured by the counts of consumed tablets and 
protocol adherence. One patient was excluded after random-
ization due to the concomitant administration of a possibly 
antioxidative agent. N o clinically significant changes were ob-
served in the weight, diet, living habits, serum enzymes, hem-
atological parameters or clinical status of the patients (Table 
1). All the presented variables were distributed normally, ex-
cept lag time in Cu-induced oxidation, where logarithmic 
transformation was carried out before comparison. 
Serum fasting lipid values are presented in Table 2. Com-
the study and after 6-week treatment periods 
After placebo 
27.1 ±0.6 
148 ± 3 
86±1 
60±2 
119±29 
96.0±1.8 
381 ±15 
31.5±3.2 
106 ±10 
After 60 mg 
lovastatin 
27.2 ±0.7 
146 ±3 
86±2 
60±2 
120 ±28 
96.4 ±1.7 
363 ±13 
38.8 ±4.7 
109±11 
Between 
treatment P 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
0.033 
N.S. 
Mean ± S.E.M. (« = 27). ANOVA with equal replication and with the factors treatment and treatment order. N.S.: P>0 .05 . 
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Table 2 
Fasting serum lipid levels before the study and after 6-week treatment periods 
Parameter 
fS-cholesterol mmol/1 
fS-LDL-cholesterol mmol/1 
fS-HDL-cholesterol mmol/1 
LDL/HDL ratio 
fS-triglycerides mmol/1 
fS-apolipoprotein AI g/1 
fS-apolipoprotein B g/1 
LDL-Chol/Apo B mmol/g 
LDL-phophorus mmol/LDL/1 plasma 
Before treatments 
and after wash-out 
7.08 ±0.23 
4.93 ±0.20 
0.91 ±0.04 
5.81 ±0.47 
2.73 ±0.31 
1.21 ±0.04 
1.37 ±0.05 
3.66±0.13 
0.97 ±0.05 
After placebo 
6.73 ±0.25 
4.79 ±0.21 
0.93 ±0.04 
5.70 ±0.66 
2.27 ±0.21 
1.24 ±0.04 
1.32 ±0.06 
3.67 ±0.11 
0.99 ±0.05 
After 60 mg 
lovastatin 
4.56 ±0.17 
2.65 ±0.11 
1.05 ±0.05 
2.76 ±0.22 
1.89±0.18 
1.32 ±0.05 
0.89 ±0.04 
3.02 ±0.10 
0.62 ±0.04 
Between 
treatment P 
< 0.0001 
< 0.0001 
0.002 
< 0.0001 
0.006 
0.003 
< 0.0001 
< 0.0001 
< 0.0001 
Mean ± S.E.M. (« = 27). ANOVA with equal replication and with the factors treatment and treatment order. N.S.: P>0.05. 
pared to the placebo period, lovastatin treatment decreased 
total cholesterol by 32%, LDL cholesterol by 45%, triglycer-
ides by 17% as well as the LDL/HDL cholesterol ratio by 52% 
and increased HDL cholesterol by 13%. All these changes 
were statistically significant (Table 2). The apolipoprotein A-
I concentration was enhanced slightly (7%). Apolipoprotein B 
decreased less than LDL cholesterol during lovastatin treat-
ment. It diminished on average by 33%, and LDL cholesterol/ 
Apo B ratio reduced by 18%>. The mean plasma phospholipid 
content in LDL decreased during lovastatin treatment by 38% 
compared to that during placebo, as can be seen in Table 2. 
LDL ubiquinol in plasma decreased by 47% during lova-
statin treatment ( P < 0.0001, Table 3). The reduction in LDL 
a-tocopherol concentration in plasma, 42%, was almost the 
same as decrease in LDL cholesterol. When adjusted to LDL 
phosphorus, there was no significant difference in a-tocopher-
ol content in LDL after the lovastatin period compared to 
that after placebo. However, there was a slight but significant 
decrease of 13% in LDL ubiquinol content after lovastatin 
treatment as measured per phosphorus in LDL (Table 3). 
Consumption of LDL antioxidants during ex vivo peroxyl 
radical attack was well-fitted in a linear function. The mean 
correlation coefficient was 0.96 in ubiquinol fits and 0.99 in a-
tocopherol fits. An individual example is presented in Fig. 1. 
Fig. 2 shows the mean curves of ubiquinol and a-tocopherol 
consumption after both lovastatin and placebo treatments. 
The slope measured from a-tocopherol consumption curve 
was statistically significantly (P< 0.001) steeper on lovastatin 
treatment than that during placebo (Table 3). The difference 
between the treatments in the consumption rate of ubiquinol 
did not reach statistical significance (Table 3). When calculat-
ing the depletion time using the rate of consumption, both 
ubiquinol and a-tocopherol were exhausted significantly faster 
after lovastatin treatment compared to that after placebo 
treatment, by 24 and 36%, respectively (Table 3). 
Lag time in Cu-induced oxidation of LDL decreased stat-
istically significantly during statin therapy, by 7% (P = 
0.0077). Protein-corrected maximal absorbance at 247 nm de-
creased by 8% (P = 0.0001). The slope of the absorbance-time 
curve in Cu-induced oxidation describing the maximal oxida-
tion rate, did not change during the different treatment peri-
ods (Table 4). 
4. Discussion 
Recent studies have shown that the treatment of hyperchol-
esterolemic CHD patients with HMG-CoA reductase inhibi-
tors does not only result in improved angiographic measure-
ments and fewer cardiovascular events [17] but also decreases 
both CHD and overall mortality [18]. The positive prognostic 
effects have been confirmed both in primary [19] and second-
ary prevention of CHD [18,20]. Lovastatin decreases LDL 
cholesterol and increases HDL cholesterol in serum [21], but 
the other qualitative effects are scarcely explored. Statins re-
duce the plasma level of ubiquinone, which can be preserved 
by exogenous ubiquinone administration [22]. However, the 
effects of statins on LDL cholesterol to ubiquinol ratio have 
been contradictory [23-25]. We found that LDL ubiquinol 
was diminished during lovastatin treatment compared to 
that on placebo. A question has arisen, if the lowered 
CoQio concentration after statin treatment can provide suffi-
cient antioxidative potential [26]. 
Table 3 
Kinetic parameters of LDL-antioxidants before the study and after 6-week treatment periods 
Parameter Before treatments and 
after wash-out 
After placebo After 60 mg 
lovastatin 
Between 
treatment P 
LDL ubiquinol 
Observed value before oxidation nmol/1 plasma 
Observed value before oxidation mmol/mol P; 
Estimated level at start of oxidation mmol/mol Pi 
Rate of consumption umol/mol Pi/min 
Calculated total depletion time min 
LDL tocopherol 
Observed value before oxidation nmol/1 plasma 
Observed value before oxidation mmol/mol P; 
Estimated level at start of oxidation mmol/mol Pi 
Rate of consumption mmol/mol P;/min 
Calculated total depletion time min 
693 ± 89 
0.696 ±0.063 
0.648 ±0.052 
58.1 ±5.3 
11.7 ±0.62 
13.611.1 
13.810.8 
13.8 + 0.8 
1.4810.16 
10.910.9 
662 + 77 
0.64110.052 
0.60110.047 
52.314.9 
12.1 ±0.52 
13.2+1.1 
13.0±0.7 
12.8 ±0.7 
1.3910.13 
10.910.8 
354146 
0.55810.052 
0.50510.047 
59.215.8 
9.110.69 
7.710.7 
12.511.0 
12.110.9 
2.1210.20 
6.810.6 
< 0.0001 
0.037 
0.015 
N.S. 
0.0022 
< 0.0001 
N.S. 
N.S. 
0.0009 
< 0.0001 
Mean!S.E.M. (n = 27). ANOVA with equal replication and with the factors treatment and treatment order. N.S.: P>0.05. 
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Fig. 1. An example of consumption of a-tocopherol and ubiquinol 
in LDL during oxidation with AMVN. Concentrations are corrected 
with LDL-phophorus. Consumption rate (linear regression coeffi-
cients): —0.95 mmol/mol Pj/min (r = 0.99) for a-tocopherol and —64 
umol/mol Pi/min (r = 0.98) for ubiquinol. 
In the present study a significant shortening in the depletion 
time of L D L ubiquinol and a-tocopherol during radical at-
tack was observed during lovastatin therapy. This was asso-
ciated with diminished resistance of L D L to oxidative stress 
produced by CUSO4. Radical exposure rate produced by the 
thermal decomposition of an azo-compound was constant for 
each sample regardless of its L D L and antioxidant concentra-
tions. Hence, the shortened depletion times of the ubiquinol 
and a-tocopherol in AMVN-induced oxidation can be ex-
pected. However, in Cu-induced oxidation L D L amount in 
oxidation cuvette was constant. The change in lag time de-
scribes decreased antioxidative defence during efficient lova-
statin therapy. Both quantitative, and possibly qualitative 
change in L D L lipid composition may explain decrease in 
the maximal protein-normalized concentration of conjugated 
dienes. 
Considering the smaller decrease of apoB than that of L D L 
antioxidants, the antioxidative defence in an individual L D L 
particle is weaker during effective lovastatin therapy. This 
may implicate loss of water-phase antioxidants. We did not 
measure the levels of ascorbic acid, protein-SH groups [27] or 
bilirubin [28,29]. N o r were the plasma hydroperoxides meas-
ured, which have been reported to be elevated in hyperchol-
esterolemic patients [30]. Serum urate did not change signifi-
cantly during lovastatin treatment (Table 1). 
A recent study by the group of Esterbauer has shown that 
apoB as a lipid core protein participates in the first line L D L 
oxidation processes [31]. In the angiographic M A R S study, 
the lovastatin treatment reduced L D L more than apoB, by 
45 and 26%, respectively [32]. ApoB was reduced less than 
.4 
B 
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18 21 
Fig. 2. Consumption of ubiquinol (A) and a-tocopherol (B) in LDL 
during oxidation with AMVN. Concentrations are corrected with 
LDL-phophorus: mmol/mol P;. Mean± S.E.M. (n = 27). Symbols: 
open, placebo; closed, lovastatin. 
L D L cholesterol on lovastatin (20 mg once daily) treatment 
in both high-fat and low-fat diet periods, 21 vs. 27% and 20 
vs. 27%, respectively [33]. Our results agree with these pre-
vious studies. 
When A M V N was used as a radical generator, L D L a-
tocopherol was depleted faster than L D L ubiquinol, which 
is in contrast to earlier studies [5,27,34]. The reason for this 
phenomenon could be the high A M V N concentration we 
used, and thus faster generation of radicals. With copper-in-
duced oxidation an increase in pro-oxidant concentration has 
Table 4 
Conjugated diene formation measured as absorbance at 247 nm during Cu-induced oxidation of LDL before the study and after 6-week treat-
ment periods 
Parmater 
Lag time min 
Maximal oxidation rate umol/1/min 
Maximal protein-normalized conjugated dienes umol/mg 
Before treatments 
and after wash-out 
64.4 ±1.6 
.484 ±.021 
516.4± 15.3 
After placebo 
63.5 ±2.2 
.468 ±.017 
526.3 ±13.5 
After 60 mg 
lovastatin 
59.5 ±1.5 
.455 ±.019 
482.6 ±12.7 
Between 
treatment P 
0.0077 
N.S. 
0.0001 
Mean ± S.E.M. (« = 27). ANOVA with equal replication and with the factors treatment and treatment order. N.S.: P>0 .05 . 
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caused a significant decrease in the lag time of conjugated 
diene formation [35]. We made all antioxidant measurements 
after the study. Therefore, it is possible that in spite of careful 
precautions, minimal oxidation had happened before the anal-
ysis. This possibility does not affect our results, because of the 
placebo-controlled, double-masked and cross-over design of 
the study. N o period or carry-over effect was observed in 
the study. Even if L D L had already been minimally oxidized 
before analysis, the results indicate that lovastatin has made 
LDL, in vivo or ex vivo, more vulnerable. 
One explanation to our findings could be the relatively 
short treatment period of 6 weeks used in this study. It may 
happen that during the first weeks of statin treatment a shift 
in the age distribution of the L D L particle pool to older 
particles occurs because of the depletion of younger ones by 
the inhibited cholesterol synthesis. Older L D L particles per se 
are less resistant to oxidation than younger ones [36]. In an-
other study, an early increase in autoantibodies to oxidized 
L D L was associated with a decrease in L D L during statin 
treatment [37]. However, a later decrease of IgG autoantibod-
ies by 12 months of treatment was also observed [37]. Another 
reason for a seeming discrepancy with the previous studies 
[23,38] might be the dose of the statin. The daily dose of 60 
mg lovastatin was chosen to ensure the therapeutic efficacy on 
L D L cholesterol in the hypercholesterolemic C H D men. 
In conclusion, lovastatin shortened significantly the deple-
tion time of the L D L antioxidants ubiquinol and oc-tocopher-
ol during AMVN-induced L D L peroxidation. Parallelly, lag 
time in Cu-induced oxidation of L D L was also reduced. It 
needs to be clarified whether ubiquinone and/or vitamin E 
substitution could preserve the antioxidative capacity of 
L D L in the early phase of oxidative stress during statin ther-
apy. 
Acknowledgements: This work has been supported by grants from 
Hilkka and Vaino Kiltti Foundation, Hameenlinna, Finland, Tam-
pere University Hospital and the Finnish Academy. We also thank 
Leiras Oy, Turku, Finland for technical support in masking the study 
and monitoring the trial. We appreciate professional aid of Dr. Terho 
Lehtimaki,Dr. Tiina Solakivi, Mrs. Marita Svard, MSc. Paivi Holm, 
Dr. Bjorn Astrom, Mrs. Marja Tanhuanpaa, Mrs. Annukka Vahanen, 
and Dr. Veli-Matti Lehtola. 
References 
[1] Goldstein, J.L. and Brown, M.S. (1990) Nature (London) 343, 
425-430. 
[2] Aberg, F., Appelkvist, E.-L., Dallner, G. and Ernster, L. (1992) 
Arch. Biochem. Biophys. 295, 230-234. 
[3] Hanaki, Y., Sugiyama, S., Ozawa, T. and Ohno, M. (1993) Clin. 
Invest. 71, S112-S115. 
[4] Mohr, D., Bowry, V.W. and Stocker, R. (1992) Biochim. Bio-
phys. Acta 1126, 247-254. 
[5] Maquire, J.J., Kagan, V., Ackrell, B.A.C., Serbinova, E. and 
Packer, L. (1992) Arch. Biochem. Biophys. 292, 47-53. 
[6] Kontush, A., Hiibner, C , Finckh, B., Kohlschutter, A. and Bei-
siegel, U. (1995) Biochim. Biophys. Acta 1258, 177-187. 
[7] Tribble, D.L., Van den Berg, J.J.M., Motchnik, PA., Ames, 
B.N., Lewis, D.M., Chait, A. and Krauss, R.M. (1994) Proc. 
Natl. Acad. Sci. USA 91, 1183-1187. 
[8] EC Note for Guidance (1990) Good Clinical Practice for Trials 
on Medicinal Products in the European Community. 111/3976/88-
EN. 
[9] Wieland, H. and Seidel, D. (1983) J. Lipid Res. 24, 904-909. 
[10] Niki, E., Yamamoto, Y., Komuro, E. and Sato, K. (1991) Am. J. 
Clin. Nutr. 53, 201S-205S. 
[11] Lang, J.K., Gohil, K. and Packer, L. (1986) Anal. Biochem. 157, 
106-116. 
[12] Peterson, G.L. (1983) Methods Enzymol. 91, 95-119. 
[13] Esterbauer, H., Striegl, G., Puhl, H. and Rotheneder, M. (1989) 
Free Radic. Res. Commun. 6, 67-75. 
[14] Fiske, C.H. and SubbaRow, Y. (1925) J. Biol. Chem. 66, 375-
400. 
[15] Itaya, K. and Ui, M. (1966) Clin. Chim. Acta 14, 361-366. 
[16] Lehtimaki, T., Moilanen, T., Viikari, J., Akerblom, H., Ehn-
holm, C , Ronnemaa, T., Marniemi, J., Dahlen, G. and Nikkari, 
T. (1990) J. Lipid Res. 31, 487-495. 
[17] Superko, H.R. and Krauss, R.M. (1994) Circulation 90, 1056-
1069. 
[18] Scandinavian Simvastatin Survival Study Group (1994) Lancet 
344, 1383-1389. 
[19] Shepherd, J., Cobbe, S.M., Ford, I., Isles, C.G., Lorimer, A.R., 
Macfarlane, P.W., McKillop, J.H., Packard, C.J. and West of 
Scotland Coronary Prevention Study Group (1995) N. Engl. J. 
Med. 333, 1301-1307. 
[20] Sacks, F.M., Pfeffer, M.A., Moye, L.A. and Rouleau, J.L. et al. 
(1996) N. Engl. J. Med. 335, 1001-1009. 
[21] Tikkanen, M.J., Helve, E., Jaattela, A., Kaarsalo, E., Lehtonen, 
A., Malbecq, W., Oksa, H., Paakkonen, P., Salmi, J., Veharanta, 
T., Viikari, J., Aarynen, M. and Finnish Lovastatin Study Group 
(1988) Am. J. Cardiol. 62, 35^13. 
[22] Bargossi, A.M., Battino, M., Gaddi, A., Fiorella, P.L., Grossi, 
G., Barozzi, G., Di Giulio, R., Descovich, G., Sassi, S., Genova, 
M.L. and Lenaz, G. (1994) Int. J. Clin. Lab. Res. 24, 171-176. 
[23] Chirlanda, G., Oradei, A., Manto, A., Lippa, S., Uccioli, L., 
Caputo, S., Greco, A.V. and Littarru, G.P. (1993) J. Clin. Phar-
macol. 33, 226-229. 
[24] Watts, G.F., Castelluccio, C , Rice-Evans, C , Taub, N.A., 
Baum, H. and Quinn, P.J. (1993) J. Clin. Pathol. 46, 1055-1057. 
[25] Laaksonen, R., Ojala, J.-P., Tikkanen, M.J. and Himberg, J.J. 
(1994) Eur. J. Clin. Pharmacol. 46, 313-317. 
[26] Appelkvist, E.L., Edlund, C , Low, P., Schedin, S., Kaln, A. and 
Dallner, G. (1993) Clin. Invest. 71, S97-S102. 
[27] Halliwell, B., Hu, M.-L., Louie, S., Duvall, T.R., Tarkington, 
B.K., Motchnik, P. and Cross, C.E. (1992) FEBS Lett. 313, 
62-66. 
[28] Neuzil, J. and Stocker, R. (1994) J. Biol. Chem. 269, 16712-
16719. 
[29] Wu, T.-W., Fung, K.-P. and Yang, C.-C. (1994) Pharmacol. Lett. 
54, 477-481. 
[30] Chirico, S., Smith, C , Marchant, C , Mitchinson, M.J. and Hal-
liwell, B. (1993) Free Radic. Res. Commun. 19, 51-57. 
[31] Giessauf, A., Steiner, E. and Esterbauer, H. (1995) Biochim. 
Biophys. Acta 1256, 221-232. 
[32] Blankenhorn, D.H., Azen, S.P., Kramsch, D.M., Mack, W.J., 
Cashin-Hemphill, L., Nodis, H.N., DeBoer, L.W.V., Mahrer, 
P.R., Masteller, M.J., Vailas, L.I., Alaupovic, P., Hirsch, L.J. 
and MARS Resarch Group (1993) Ann. Intern. Med. 119, 
969-976. 
[33] Hunninghake, D.B., Stein, E.A., Dujovne, C.A., Harris, W.S., 
Feldman, E.B., Miller, V.T., Tobert, J.A., Laskarzewski, P.M., 
Quiter, E., Held, J., Taylor, A.M., Hopper, S., Leonard, S.B. and 
Brewer, B.K. (1993) N. Engl. J. Med. 328, 1213-1219. 
[34] Stocker, R., Bowry, V.W. and Frei, B. (1991) Proc. Natl. Acad. 
Sci. USA 88, 1646-1650. 
[35] Gieseg, S.P. and Esterbauer, H. (1994) FEBS Lett. 343, 188-194. 
[36] Walzem, R.L., Watkins, S., Frankel, E.N., Hansen, R.J. and 
German, J.B. (1995) Proc. Natl. Acad. Sci. USA 92, 7460-7464. 
[37] Bui, M.N., Caulfield, M.T., Katz III, P.C., Richard, O. and 
Rackley, C.E. (1996) J. Am. Coll. Cardiol. 27, 413A. 
[38] Laaksonen, R., Jokelainen, K., Laakso, J., Sahi, T., Harkonen, 
M., Tikkanen, M.J. and Himberg, J.J. (1996) Am. J. Cardiol. 77, 
851-854. 
